Apr 17, 2025, 11:17

Oncomine Clinical Research Grant Program

The Oncomine Clinical Research Grant Program, offered by Thermo Fisher Scientific, supports investigator-initiated studies (IIS) and educational projects focused on molecular profiling in oncology. The goal is to advance high-quality research in precision oncology and broaden access to molecular diagnostics globally. Proposals are reviewed by internationally recognized external experts in collaboration with Thermo Fisher’s medical and scientific leadership. Awards are based strictly on scientific merit.

Eligibility Criteria

Open to researchers proposing oncology-related projects involving molecular profiling
Proposals must be submitted in English and must detail all activities to be completed within 12 months
A budget is required, with a maximum request of 200,000 USD
Funding is provided in accordance with local legislation
Open to global applicants affiliated with a recognized institution or organization

Funding Details

Amount: Up to 200,000 USD per project
Duration: Up to 12 months
Use of Funds: Budget must outline the use of requested funds for research-related activities
Note: Final report submission is required upon project completion

Application Deadline

Submission Period: April 1 – May 2, 2025
Decision Notification: 6 to 8 weeks after submission period ends

How to Apply

Submit via the online portal or email application to [email protected]

cancer Cancer Biomarkers Cancer diagnostics cancer genomics cancer research funding Clinical Sequencing investigator-initiated studies molecular profiling OncoDaily Oncology oncology research Oncomine Oncomine grant Precision Medicine Research Grants Thermo Fisher Scientific

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology